Magnesium in disease

Helmut Geiger¹ and Christoph Wanner²

¹Klinikum der J.W. Goethe-Universität, Medizinische Klinik III/Nephrologie, Frankfurt/Main, Germany and ²Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik I, Würzburg, Germany

Correspondence and offprint requests to: Helmut Geiger; Email: h.geiger@em.uni-frankfurt.de

Abstract
Although the following text will focus on magnesium in disease, its role in healthy subjects during physical exercise when used as a supplement to enhance performance is also noteworthy. Low serum magnesium levels are associated with metabolic syndrome, Type 2 diabetes mellitus (T2DM) and hypertension; consequently, some individuals benefit from magnesium supplementation: increasing magnesium consumption appears to prevent high blood pressure, and higher serum magnesium levels are associated with a lower risk of developing a metabolic syndrome. There are, however, conflicting study results regarding magnesium administration with myocardial infarction with and without reperfusion therapy. There was a long controversy as to whether or not magnesium should be given as a first-line medication. As the most recent trials have not shown any difference in outcome, intravenous magnesium cannot be recommended in patients with myocardial infarction today. However, magnesium has its indication in patients with torsade de pointes and has been given successfully to patients with digoxin-induced arrhythmia or life-threatening ventricular arrhythmias. Magnesium sulphate as an intravenous infusion also has an important established therapeutic role in pregnant women with pre-eclampsia as it decreases the risk of eclamptic seizures by half compared with placebo.

Keywords: cardiovascular disease; diabetes mellitus; magnesium; metabolic syndrome; pre-eclampsia/eclampsia

Introduction
Magnesium has numerous physiological functions in the body—in health as in disease (also see de Baaij et al. [1] in this supplement). With regard to muscle function, magnesium affects oxygen uptake, energy production and electrolyte balance. Magnesium requirement is higher during sports, particularly during strenuous workouts, as when sweating copiously, the need for magnesium increases considerably. During physical exercise, magnesium is re-distributed within the body to accommodate altered metabolic needs. Essential minerals, or the use of magnesium supplements, are recommended to enhance performance. Athletes usually consume sufficient minerals—including magnesium—via high-energy diets. However, this is not always the case when restricting or reducing diets to maintain or reduce body weight. This can result in insufficient magnesium intake and a subsequent decrease in physical performance [2, 3]. While even a marginal magnesium deficiency can impair exercise performance, magnesium supplementation can also boost training performance in athletes, particularly in magnesium-deficient individuals [2, 4]. Therefore, dietary magnesium supplementation in sports should be considered.

Whether magnesium supplementation is effective in reducing muscle cramps needs to be further evaluated, as noted in the conclusion of a recent evidence-based review of symptomatic treatment for muscle cramps [5]. Evidence is scarce and only two Class-II evidence trials were included in the assessment (excluded studies were those dealing with muscle cramps because of medical conditions such as cirrhosis and haemodialysis as well as trials during pregnancy). In one of these two trials included in the review, dosages of an equivalent of 12.3 mmol (300 mg) of magnesium given as magnesium citrate were studied in 46 patients suffering from chronic persistent leg cramps, and a trend in favour of magnesium for reducing muscle cramps was reported (P = 0.07) [6]. The second trial, which included 45 patients with nocturnal leg cramps, and in which 36 mmol (900 mg) magnesium citrate was given, did not reveal any significant effect on the number of muscle cramps [7]. Nonetheless, there is some evidence supporting magnesium administration in pregnant women suffering from cramps using a proposed dose of 5 mmol magnesium as a mixture of lactate and citrate in the mornings and 10 mmol in the evenings [8]. Still, these data remain controversial. In a more recent, double-blind placebo-controlled trial including 38 pregnant women suffering from leg cramps, magnesium supplementation (15 mmol/day) did not reveal any beneficial effect of magnesium on the frequency and intensity of leg cramps compared to placebo [9].

Magnesium and the metabolic syndrome
The metabolic syndrome is a disease of modern times. It is an increasing problem in developed and developing countries and is characterized by the simultaneous presence of several metabolic risk factors. It was estimated in 2002 that one quarter of American adults suffer from metabolic
syndrome [10]. Generally, the triad of obesity, hypertension and impaired glucose tolerance, as in diabetes mellitus (insulin resistance), is referred to as the metabolic syndrome. Dyslipidaemia [11], prothrombotic states (high fibrinogen and plasminogen activator inhibitor-1) and an activated acute-phase response (elevated C-reactive protein) may all also contribute to the disorder [12, 13]. To dissect the factors responsible for each single condition, the various diseases underlying the metabolic syndrome will be discussed separately in detail.

One common feature in patients with Type 2 diabetes mellitus (T2DM), hypertension and low levels of high-density lipoprotein cholesterol (HDL-C) appears to be a deficiency of magnesium. However, no data have been published about serum magnesium levels in people with the metabolic syndrome until recently [13, 14]. In 2002, results from a cross-sectional population-based study revealed an association between serum magnesium levels and the metabolic syndrome: Mexicans in their 40s with a metabolic syndrome (n = 192) were compared with an age-matched healthy control group (n = 384) [13]. Serum magnesium levels ≤0.74 mmol/L (1.8 mg/dL), corresponding to the lowest quartile of distribution were defined as low. Using this definition, serum magnesium levels were low in 66% of the patients with the metabolic syndrome compared with 4.9% in the control population (P < 0.00001). There was a strong independent association between serum magnesium levels below this threshold and the prevalence of the metabolic syndrome [odds ratio 6.8; 95% confidence interval (CI) 4.2–10.9] [13]. In a further cross-sectional analysis based on 11 686 women, originally participating in the Women’s Health Study (WHS), an inverse correlation of magnesium intake and the prevalence of the metabolic syndrome was seen in those above the age of 45 years [15]. The relationship between magnesium intake and the metabolic syndrome was also studied prospectively in younger individuals, i.e. in 5115 young Americans (aged 18–30 years), initially free of metabolic syndromes and diabetes, who were enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) study from 1985 to 1986. A total of 4637 participants were included in the analysis, and 74% showed up for the 15-year examination in 2000–2001. Within this follow-up period, 608 incident cases of metabolic syndrome were diagnosed. The findings showed that young adults with a higher magnesium intake had a lower risk of developing metabolic syndrome and that this risk was dose dependent [16].

- The metabolic syndrome is an increasing health problem in the westernized world, and is characterized by a combination of metabolic risk factors.
- Low serum magnesium levels are associated with a higher prevalence of the metabolic syndrome.
- Higher dietary magnesium intake is associated with a lower risk of developing a metabolic syndrome.

Magnesium and diabetes mellitus

T2DM is often associated with hypomagnesaemia [17], and incidence rates of 13.5–47.7% have been reported [18]. Hypomagnesaemia can be defined as serum magnesium concentrations ≤0.65 mmol/L (1.6 mg/dL) or ≥2 SD below the average in the general population [19, 20]. Hereditary factors, poor dietary intake, autonomic dysfunction, altered insulin metabolism, glomerular hyperfiltration, osmotic diuresis, recurrent metabolic acidosis, hypophosphataemia and hypokalaemia may all contribute to hypomagnesaemia in diabetic patients [18].

Magnesium deficiency has also been linked to the development of the disease as well as its severity: the lower the magnesium level the faster the deterioration of renal function in Type 2 diabetics [20]. Moreover, correction of hypomagnesaemia via dietary magnesium supplementation improved glucose handling and insulin response in elderly and non-insulin-dependent diabetics [21]. Several investigators have therefore addressed the topic of magnesium status and dietary magnesium intake, especially in diabetes mellitus.

In epidemiological studies, an inverse correlation between magnesium intake and the risk of developing diabetes mellitus was found [22–24]. The WHS enrolled a cohort of 39 345 US women aged at least 45 years. During a follow-up period of 6 years, on average, 918 women developed T2DM. The trial results support a protective role for higher magnesium intake and a reduced risk of developing T2DM, in particular in the subgroup of overweight women [24]. In two other large prospective studies—the Nurses’ Health Study (NHS) initiated in 1976 and the Health Professionals Follow-up Study (HPFS), which began in 1986—an inverse correlation between magnesium intake and the risk of developing T2DM was observed for women as well as for men [23]. The investigators examined the association between magnesium intake and risk of T2DM in 85 060 women and 42 872 men without any previous history of diabetes, cardiovascular disease or cancer at baseline. After 18 years follow-up, 4085 cases of T2DM were documented in women, and after 12 years follow-up, 1333 T2DM cases were found in men. When comparing the highest and lowest magnesium consumption, the relative risk for T2DM was in the highest-magnesium group 0.66 in women, (95% CI 0.60–0.73, P < 0.001) and 0.67 in men (95% CI 0.56–0.80, P < 0.001) [23]. Furthermore, in the Atherosclerosis Risk in Communities Study (ARIC), a low serum magnesium level was found to be a strong independent predictor of incident T2DM among middle-aged white participants [22]. Recently, a meta-analysis of seven prospective cohort studies and 286 668 participants revealed that magnesium intake was inversely associated with the incidence of T2DM. The authors suggested that an increased consumption of magnesium-rich food, such as whole grains, beans, nuts and green vegetables, might reduce the risk for T2DM [25] (Figure 1).

Findings from large observational studies, carried out in various other regions in the world, have had similar results. For instance, in a large, population-based prospective study including 64 191 middle-aged Chinese women, a non-linear inverse association between calcium and magnesium consumption and the incidence of T2DM was observed after 7 years follow-up. Future controlled studies must, however, investigate whether the intake of these elements is protective for the development of T2DM in this population [26]. Moreover, it was noted in an assessment of 14 532 adults in Australia that hypomagnesaemia was on average 8.6 times more common in patients with diabetes and 10.5-fold higher in newly diagnosed diabetics than in healthy individuals [17]. This observation, however, did not hold true for the precursor states of diabetes, as no differences were
observed between healthy controls and individuals with impaired glucose tolerance or impaired fasting glucose levels [17]. In the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam Study which included 9702 men and 15 365 women, dietary intake of fibre and magnesium was evaluated by validated food questionnaires assessing the risk of T2DM [27]. In light of the evidence from this investigation and a meta-analysis including various previous studies, the authors summarized that higher magnesium intake, along with higher fibre consumption, might be able to decrease the risk of developing T2DM [27].

But conflicting data also exist: in a cohort of 17 592 Japanese between 40 and 65 years of age, investigators observed that dietary magnesium intake was inversely associated with diabetes incidence in both genders [28]. In contrast, a prospective Japanese study including 25 872 men and 33 919 women, aged 45–75 years, with no history of diabetes, demonstrated only a small correlation in men after 5 years of observation. They noted that magnesium intake might not be appreciably associated with the risk of T2DM in Japanese adults. The authors conceded that magnesium might improve insulin resistance but had no clear explanation for the smaller risk association among these Japanese patients compared with western populations. They further speculated that the observed differences could be ascribed to the lean body mass of Asian populations [29]. The US Black Women’s Health Study (BWHS) showed that a diet rich in magnesium was shown to be associated with a substantially lower risk of T2DM in a prospective cohort study including 41 186 participants with an 8-year follow-up (1995–2003) [30]. In contrast, however, little or no association was observed among black participants in the ARIC study, possibly because any modest benefit from magnesium was overshadowed by the extraordinarily high incidence of T2DM in blacks. Nonetheless, as mentioned above, there was a strong correlation between low-serum magnesium levels and the incidence of T2DM in middle-aged white participants of the same trial [22]. As a consequence of the aforementioned observations, a controversy has ensued concerning the causal association between hypomagnesaemia and the risk for diabetes mellitus. In addition, hypomagnesaemia was identified as a risk factor for the development and progression of diabetic retinopathy [31]. Finally, lower magnesium levels also appear to be associated with a more rapid decline of renal function in patients with T2DM [20]. Patients with serum magnesium levels between 0.82 and 1.03 mmol/L (2.0–2.5 mg/dL) had the lowest deterioration of renal function and the best glycaemic control. Therefore, these levels were suggested as target serum magnesium levels for diabetic patients [18].

Possible underlying mechanisms
The mechanisms whereby hypomagnesaemia may induce or worsen existing diabetes are not well understood. It has been suggested that magnesium regulates cellular glucose metabolism directly because it serves as an important co-factor for various enzymes and acts as a second messenger for insulin [32–34] (also see Jahnen-Dechent and Ketteler [35] in this supplement).

It was also observed that insulin enhances intracellular magnesium uptake [36] and this in turn mediates diverse effects ascribed to insulin [32]. Furthermore, hypomagnesaemia may induce altered cellular glucose transport, reduced pancreatic insulin secretion, defective post-receptor insulin signalling and/or altered insulin–insulin receptor interactions [18] and thus aggravate insulin resistance [37].

Therapeutic considerations
Two studies investigated the effect of magnesium supplementation in non-diabetic insulin-resistant individuals: one study in 60 non-diabetic hypomagnesaemic subjects describes in a double-blind, placebo-controlled randomized trial over 3 months, that daily administration of 300 mg (12.3 mmol) magnesium significantly improved insulin sensitivity [38]. These data were confirmed in a very recent placebo-controlled randomized trial in 52 normomagnesaemic, but overweight and insulin-resistant subjects, in which Mg supplementation over 6 months resulted in a significant improvement of fasting plasma glucose and insulin sensitivity indices compared to placebo [39].

Whether patients with established T2DM benefit from the administration of magnesium was evaluated in a meta-analysis of nine randomized-controlled trials enrolling 370 participants [40]. Dosage, indications and inclusion criteria varied. Number of patients in the single studies were relatively small and the outcome variable. Oral magnesium supplementation at a median dose of 15 mmol/day used as adjunct therapy for 4–16 weeks was found to be significant regarding lowering fasting glucose levels, but only marginally effective in lowering HbA1C and increasing HDL-C [40]. One of these studies was performed in hypomagnesaemic patients and revealed the most promising results [41]. Another study, investigating the effect on lipid profiles which was not considered in the meta-analysis cited above, as a combination of magnesium and vitamin C and E was used, saw an increase in HDL-C and Apo A1 but no other changes in lipids including triglycerides [42].

Magnesium supplements alone [43] or in combination with other supplements (i.e. Zinc, vitamin E, C and B complex) [44] have also been described as being useful in treating diabetic neuropathy [43, 44] and depression [45].

In conclusion, daily magnesium administration may play a role in pre-diabetic and/or diabetic subjects, but more and larger trials are needed to establish its definitive role.
Magnesium and cardiovascular disease

Death from cardiovascular disease is common and demographical changes mean that deaths from this cause are likely to increase even further. Many cardiovascular disorders are associated with changes in magnesium levels; in particular, those affecting the myocardium and involving blood pressure control [31]. The investigators of a recent epidemiological study—a 5-year follow-up of the population-based Study of Health in Pomerania (SHIP) (n = 212 157)—found that low serum magnesium levels predicted cardiovascular and all-cause mortality [46]. They were also able to show that low serum magnesium concentrations—regardless of other cardiovascular risk factors—were associated with the long-term gain of left ventricular mass [47], a significant predictor for adverse cardiovascular events.

Magnesium and hypertension

Not only left ventricular hypertrophy but also high blood pressure has been linked to hypomagnesaemia. An inverse relationship between magnesium and blood pressure is apparent according to various study results [18]. Some data even support a role for magnesium in the pathophysiology of essential hypertension [48–50]. Moreover, investigators reported that doses of anti-hypertensive drugs needed to be higher in patients with a magnesium deficiency than in those without [51].

For the most part, results of clinical trials showed magnesium deficiency (in serum and/or tissue) to a certain degree in hypertensive subjects, linking low magnesium levels to a significant undesirable effect on blood pressure [52]. Total magnesium content in red blood cells, as measured by atomic absorption spectroscopy, was significantly reduced in hypertensive white men and women, and in black men, were inversely related to systolic blood pressure (Figure 2) [54]. This study included a total of 15 248 participants, aged 45–64 years.

Not all investigators detected low magnesium serum concentrations in people with hypertension. Hiraga et al. [55]—conceding that they were not able to provide an explanation—even observed increased cytosolic-free magnesium concentrations in essential hypertension. Despite these inconsistencies in respect to magnesium status and high blood pressure, some hypertensive individuals consistently demonstrate hypomagnesaemia. Among those are patients with obesity, insulin resistance, hypertriglyceridemia, severe forms of hypertension, hyperaldosteronism (i.e. volume-dependent hypertension), pregnancy-induced hypertension as well as patients of African-American descent [56–58]. Patients with high blood pressure, therefore, do not seem to represent a homogeneous group. It was speculated that reduction in total intracellular magnesium may only play a role in certain subgroups of patients (who—for the time being—cannot be identified with specific clinical characteristics [53]. Obviously, magnesium deficiency is not present in all hypertensive patients. Conversely, not all individuals with hypomagnesaemia suffer from high blood pressure [58]. Moreover, when interpreting the results of older investigations, one has to bear in mind that only recently have certain highly specific techniques become available, such as selective fluorescent Mg2+ probes and Mg2+-specific ion-selective electrodes, and these may account for some degree of variation between older and more recent studies.

Whereas serum magnesium-concentrations are not always directly related to arterial hypertension or the development of blood pressure over time [47], reviews of epidemiological and observational studies have shown an inverse relationship between dietary magnesium intake and blood pressure levels [59]. Substantial epidemiological evidence for a correlation between magnesium and blood pressure is derived from the Honolulu Heart Study [49]. In this trial, 61 dietary variables were investigated in 615 men of Japanese descent living in Hawaii and who had no history of hypertension. The results revealed that among these variables, it was dietary magnesium consumption that showed the strongest inverse association with blood pressure.

Similar associations were observed in the ARIC trial between dietary magnesium intake and systolic blood pressure in white women and in blacks (Figure 3) and for diastolic blood pressure [54]. A comprehensive meta-analysis on this subject, however, demonstrated a huge variability of the results without a significant association between magnesium intake and blood pressure [50].

Possible underlying mechanisms. In spite of considerable research, the exact underlying causes for altered magnesium metabolism in hypertensive individuals remain unclear. It is assumed that inadequate dietary magnesium intake or a malfunction in magnesium metabolism can lead to vasoconstriction and endothelial damage [60–62]. Magnesium deficiency—in particular when combined with stress and catecholamine secretion—might lead to enhanced entry of calcium into vascular smooth muscle cells, which in turn can result in increased arteriolar tone and coronary spasm. Hypertension and its complications may also be the final consequences of increased calcium influx and contraction of arterial smooth muscle cells [31, 63, 64]. Moreover, it was observed that magnesium—often referred to as a ‘natural calcium antagonist’ (also see Jahnen-Dechent and Ketteler [35] in this supplement)—acts on most types of calcium channels in vascular smooth muscle cells exerting substantial arterial blood pressure-lowering properties, resulting in a reduction of peripheral and cerebral vascular resistance. Apparently, vasodilation is mediated by blocking calcium influx and competitive inhibition of calcium binding [65]. In vivo and in vitro studies in animals (pregnant rats) demonstrated magnesium-induced relaxation of smooth muscle. Such findings suggest the vasodilatory potential of magnesium in large arteries such as the aorta [66–68], in smaller resistance vessels as the mesenteric arteries and in the cerebral arteries [65, 69–72].
Therapeutic considerations. Although previous studies evaluating anti-hypertensive effects of magnesium supplementation also produced contradictory results, the therapeutic value of magnesium in hypertension was mentioned as early as 1925 [74]. Since then, considering the inexpensive nature of magnesium, researchers have suggested a putative role for magnesium in the routine management of hypertension [14, 75, 76].

In one trial, oral magnesium supplementation was associated with small, but consistent and significant, reductions in mean 24-h systolic and diastolic blood pressure in individuals with mild hypertension (n = 48) [48]. When magnesium concentrations were assessed after magnesium supplementation, serum and intracellular levels had indeed increased, as did magnesium excretion via the urine. Intracellular potassium levels had also risen, while intracellular calcium and sodium concentrations had decreased. In a meta-analysis, evaluating 1220 individuals from 20 randomized clinical trials, significant dose-dependent blood pressure reductions were reported after magnesium supplementation [50]. Other studies similarly showed significant blood pressure-lowering effects of oral and/or intravenous magnesium administration [75, 76]. But, other trials have failed to demonstrate blood pressure-lowering effects of magnesium supplementation [77, 78]. This also holds true for the Trial of Hypertension Prevention Study (TOHP), in which no benefit of magnesium therapy was found in 698 patients who had been followed up for a 6-month period [79]. A review by the Cochrane Collaboration in 2009, investigating magnesium supplementation for the management of primary hypertension in 12 randomized-controlled trials with 545 participants found no reduction in systolic blood pressure, but a small, albeit statistically significant, reduction in diastolic blood pressure [80]. A recent comprehensive analytical review (meta-analysis) of 44 studies of oral magnesium therapy in hypertension came to the conclusion that magnesium supplementation may enhance the blood pressure-lowering effect of anti-hypertensive medications [81]. The inconsistency of the study results might be explained by the different types and dosages of magnesium salts, which were given in the various trials as well as by the heterogeneity of the study populations. Numerous epidemiological and clinical investigations support the hypothesis that increased magnesium intake contributes to the prevention of hypertension and cardiovascular disease [59, 82-86]. However, magnesium administration decreased blood pressure levels in several [48, 87-90] but not all clinical trials [50, 80, 81, 91-94]. Thus, before making definitive therapeutic recommendations, further controlled interventional long-term trials, including carefully characterized hypertensive patients, are needed [95].

Atherosclerosis
Atherosclerosis is a well-known risk factor for cardiovascular disease, potentially triggering myocardial infarction and stroke. The pathogenesis of atherosclerosis, however, is complex and like endothelial dysfunction and hyperlipidaemia, hypomagnesaemia has been identified as a major risk factor [96]. Thus, magnesium deficiency may alter lipid metabolism and change the rate of the atherosclerotic process [97].

Animal data have revealed that dietary magnesium deficiency exacerbates atherosclerosis and vascular damage [98, 99]. Experimental magnesium deficiency induced an inflammatory syndrome in animal models, characterized by macrophage and white blood cell activation, release of...
effects exerted by certain drugs such as clopidogrel [108]. Recent epidemiological evidence supports the hypothesis that magnesium intake is inversely associated with C-reactive protein concentration [102]. It is also possible that magnesium deficiency contributes to inflammation via changes in proatherogenic lipoprotein concentrations, i.e. accumulation of triglyceride-rich lipoproteins accompanied by elevated plasma apolipoprotein B levels and a decline in HDLs [102].

**Therapeutic considerations.** Dietary magnesium consumption appears to play a crucial modulatory role in controlling lipid metabolism [37]. Although the mechanisms are poorly understood, studies demonstrated that increased intake of dietary magnesium can lower blood triglyceride and increase HDL-C levels [109]. It was reported that oral supplementation with magnesium chloride (up to 26.3 mmol/day) resulted in a significant increase in the HDL-C fraction [96]. In addition, magnesium intake was inversely associated with markers of systemic inflammation and endothelial dysfunction in women [110] and also postmenopausal women [111].

**Possible underlying mechanisms.** Even at the beginning of the 20th century after the discovery of magnesium as an essential nutrient, magnesium deficiency was linked to inflammation [102]. Treatment effects in preventing cardiovascular disease were thought to be related to the reduction of the inflammatory response. Magnesium also reduces vulnerability to oxygen-derived free radicals, improves endothelial function and inhibits platelet aggregation and adhesion [108] and thus its properties resemble the

- Dietary magnesium deficiency might aggravate atherosclerosis and vascular damage.
- In epidemiological studies, low serum magnesium level was associated with a higher risk of coronary artery disease and a higher risk of stroke.
- Magnesium supplementation might lead to an increase in the HDL-C fraction.

**Acute myocardial infarction**

Magnesium deficiency has been associated with induction of severe vascular damage in the heart, acceleration of the development of atherosclerosis, vasoconstriction of the coronary arteries, increase in blood pressure and enhanced platelet aggregation [99]. Hypomagnesaemia seems to be involved in the pathogenesis of ischaemic heart disease by altering lipoprotein composition, predisposing individuals to atherosclerosis [112]. In animal models of myocardial infarction, magnesium administration prior to reperfusion led to a reduction in infarct size [113].

**Possible underlying mechanisms.** The results of autopsy studies reveal that patients who had died from ischaemic heart disease had lower magnesium levels in myocardium and muscle compared with those who had died from non-cardiac causes [114]. It was observed that during myocardial ischaemia, total intracellular magnesium decreases while free ionized intracellular magnesium increases [115]. In addition, ischaemia leads to intracellular calcium overload—which is even more pronounced in the reperfusion phase—compromising myocardial function. It was speculated that magnesium administration reduces calcium overload because there was evidence that these two elements compete with one another for the same binding sites. Magnesium might be considered a natural 'calcium antagonist' [65] and is able to attenuate phosphate-induced apoptosis in vascular smooth muscle cells [116]. Calcium channel blockers are effective in treating certain cardiovascular disorders, particularly angina, and because
Magnesium in disease

Therapeutic considerations. Magnesium therapy has been extensively studied in the context of acute myocardial infarction in various clinical trials. The Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2), included 2316 patients who were randomized to receive intravenous magnesium sulphate or matching placebo. Patients received placebo or magnesium for 5 min before initiation of thrombolytic therapy, followed by an infusion for the next 24 h. This study showed a 24% reduction in 28-day mortality, a 25% reduced incidence of left ventricular failure and an improvement in long-term survival in terms of reduction of long-term mortality from ischaemic heart disease (average follow-up period of 2.7 years) [119, 120]. The authors concluded that early intravenous magnesium sulphate is a simple, safe and useful addition to standard procedures in acute myocardial infarction. Furthermore, its efficacy in reducing early mortality does not affect thrombolytic or antiplatelet therapy [119]. Intravenous magnesium therapy in a placebo-controlled randomized trial enrolling 194 high-risk patients not eligible for thrombolytic therapy significantly reduced incidence of arrhythmias and inhospital mortality in the verum group [121]. In contrast, the ISIS-4 trial (Fourth International Study of Infarct Survival), in which a large group of 58 050 patients with suspected acute myocardial infarction was included, did not demonstrate a beneficial effect of magnesium therapy in the acute myocardial infarction setting. The routine use of magnesium had little or no effect on mortality rates—though it did not do any harm—in patients with acute myocardial infarction [122]. The difference to the result of the LIMIT-2 trial and to the results of an earlier meta-analysis [123] have been attributed to variations in the study designs (early versus late administration of magnesium). It is noteworthy that in the ISIS-4 study, magnesium was given after reperfusion (iatrogenic or spontaneous), and this difference in timing might explain the negative result of the trial [124, 125]. In addition, it has been suggested that magnesium therapy is beneficial only in those patients not receiving, or not suitable for, thrombolytic treatment. It was also hypothesized that magnesium therapy is less beneficial in low-risk patients and more advantageous in high-risk patients [113]. But further studies confirmed the negative results of the ISIS-4 study. An Italian study, involving 150 patients with acute myocardial infarction demonstrated that intravenous magnesium given prior, during and after reperfusion, neither minimized myocardial damage nor improved short-term clinical outcome [126]. These results were again confirmed in another larger clinical trial. The MAGIC trial included 6213 high-risk patients with ST-elevation myocardial infarction. After intravenous MgSO4 bolus administration, no improvement of short-term mortality was found as compared to patients who were randomly assigned to placebo. At 30 days, an equal proportion of patients had died in both groups (15.3 versus 15.2%). No benefit or harm from magnesium administration was observed, which was also the case for patients not eligible for thrombolysis [127]. Even though there is no real explanation for the discrepancies, it was discussed whether magnesium’s proposed cardioprotective mechanisms might be interfering with the effects of standard medical regimens including aspirin, β-blockers and angiotensin-converting enzyme inhibitors not routinely used in earlier trials. Thus, the conclusion after these last clinical trials was that magnesium sulphate cannot be generally recommended for the routine administration in acute myocardial infarction [127].

Arrhythmia

Hypomagnesaemia is a possible cause of arrhythmia—both of atrial and ventricular origin—which has been discussed in the literature [128]. Certainly, it is difficult to establish a direct link between magnesium deficiency and arrhythmia because the correlation of serum and cardiac magnesium concentration is poor. Little clinical evidence exists that isolated hypomagnesaemia induces arrhythmias. To complicate matters further, hypomagnesaemia is closely related to hypokalaemia, which itself is arrhythmogenic. In addition, magnesium deficiency exacerbates potassium-mediated arrhythmia, in particular in the presence of digoxin intoxication [128, 129]. Nonetheless, the therapeutic role of magnesium in this indication has been thoroughly studied, and most investigations revealed a favourable effect when keeping magnesium concentrations within the physiological range, an effect which was enhanced when both magnesium and potassium concentrations were adjusted [58].

Possible underlying mechanisms. Anti-arrhythmogenic properties of magnesium may involve changes in the activity of calcium and potassium channels [130]. Both extracellular and cytosolic magnesium has significant effects on cardiac ion channels, which in turn may have important consequences on the duration of action potential, cell excitability and contractility [130]. Magnesium blocks calcium influx [65], reducing sinus node rate firing, prolonging AV conductance and increasing atrio-ventricular (AV) node refractoriness [58].

Therapeutic considerations. A randomized, double-blind, placebo-controlled study called Magnesium in Cardiac Arrhythmias (MAGICA), demonstrated that patients with frequent ventricular arrhythmia (n = 232) benefited from increasing dietary magnesium and potassium

magnesium mimics the effect of these drugs [117], it might protect cells during ischaemia and so limit infarct size [113]. In addition, the effects of magnesium on vascular tone, its anticoagulant properties, its ability to improve endothelial dependent vasodilation, possibly through improvement of NO release [118], theoretically may all exert a beneficial effect in acute myocardial infarction. Based on these different observations, investigators started to study magnesium replacement as an adjunctive pharmacotherapy within the setting of acute myocardial infarction.
intake in terms of a moderate but significant anti-arrhythmic effect [131]. Intravenous magnesium infusions decreased the frequency of ventricular arrhythmias after acute myocardial infarction [132–135] and reduced QT-dispersion [133]. The LIMIT-2 trial [119], however, did not reveal such an effect, even though the frequency of ventricular fibrillation was slightly reduced in the ISIS-4 trial, there was no benefit regarding survival [122]. As a consequence, there are currently no firm recommendations for the use of magnesium in the treatment of patients with arrhythmia after myocardial infarction [136].

According to guidelines [136] in patients with ventricular arrhythmia, any electrolyte imbalance should always be corrected but the administration of magnesium as an active treatment is only recommended for certain types of arrhythmia [136, 137]. These include ventricular arrhythmia-associated torsade de pointes, where magnesium has a well-established role under certain circumstances [137–143]. It is thus recommended to treat patients who present with long QT syndrome, polymorphic ventricular tachycardia and few episodes of torsade de pointes with intravenous magnesium sulphate [136, 137, 144]. These patients can be treated with magnesium sulphate intravenously as a first-line agent to terminate torsade de pointes, irrespective of serum magnesium level. Magnesium is not likely to be effective in patients with normal QT intervals [136]. The same guidelines also recommended magnesium sulphate for resuscitation of patients with pulseless ventricular fibrillation and ventricular tachycardia in cases when epinephrine, lidocaine or amiodarone prove ineffective.

Digoxin-induced arrhythmia is facilitated by hypomagnesaemia and can be terminated by magnesium administration [145, 146]. Cardiac glycosides such as digoxin are used for treatment of patients with atrial fibrillation, but digoxin is also arrhythmogenic itself in overdose [147, 148]. The American Heart Association states that magnesium is reasonable for patients who take digitalis and present with sustained ventricular arrhythmias, advanced AV block and/or asystole [136]. In fact, magnesium has been used since the 1930s for digitalis intoxication [149].

Although it has been established that there is a significant relationship between low magnesium levels and an increased incidence of atrial fibrillation [150], the role of magnesium therapy and prophylaxis of atrial fibrillation remains unclear. Even though numerous studies have investigated the role of magnesium administration in relapse prevention of atrial fibrillation [129, 151], the results are still controversial. Several publications demonstrated beneficial effects of magnesium when added to standard treatment, while others failed to do so [150–153]. This is the reason why some investigators suggest that magnesium treatment should be limited to those patients for whom other drugs are contraindicated or have been shown to be ineffective [58]. However, magnesium was successfully administered in neonates and infants to prevent post-operative arrhythmias in the setting of arterial switch operation [154].

- Electrolyte imbalances including hypomagnesaemia, often caused by the use of diuretics, should be corrected in patients suffering from arrhythmias, irrespective of the form and/or underlying cause.
- Magnesium therapy should be given to patients with ventricular arrhythmia associated with torsade de pointes who present with long QT syndrome as well as for the treatment of patients with digoxin intoxication-induced arrhythmias.
- The role of magnesium therapy in the prevention of atrial fibrillation needs to be further elucidated.

---

**Fig. 5.** Treatment effects of magnesium administration in patients with (pre-)eclampsia [169]. Magnesium led to consistent effects regardless of severity of pre-eclampsia, stage of gestation and anticonvulsant therapy. Reprinted from Altman et al. [169], Copyright (2002), with permission from Elsevier. PMR, perinatal mortality rate; *Unknown whether prior anticonvulsant treatment was given to 26 women allocated to the magnesium sulphate and 37 allocated to the placebo groups.
Magnesium and pre-eclampsia/eclampsia

For centuries, doctors have feared the occurrence of convulsions during pregnancy as they have been associated with poor prognoses for the mother and the unborn child. At first, eclampsia—associated with a 50% maternal mortality rate in earlier days—was thought to be a simple convulsive disorder. During the 19th century, eclampsia was then noted to be associated with albuminuria and hypertension, which led to an earlier diagnosis of the condition in the last century [155, 156]. Seizures in eclampsia were distinguished from other types of seizures primarily by the absence of previous history of seizures before pregnancy [156].

Pre-eclampsia is defined as a condition with hypertension, proteinuria [157], often accompanied by pathological oedema, occurring in about 6–8% of all gestations over 20 weeks [155]. It is seen more often in nulliparous women [155]. Pre-eclampsia usually regresses rapidly postpartum [155]. This complex disorder is characterized by haemoconcentration, vasoconstriction with increased peripheral resistance and reductions in cardiac output, plasma volume [158–160] and prostacyclin synthesis [161]. Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation, and thus the shift in balance of the thromboxane/prostacyclin ratio might end-up favouring vasoconstriction and platelet aggregation [155]. The observed proteinuria is associated with glomerular lesions typical for pre-eclamptic women. Circulating angiogenic factors, such as soluble vascular endothelial growth factor Type 1 receptor (also known as soluble Fms-like tyrosine kinase 1, sFlt1) are suggested to contribute to the development of the disease [162].

The hypothesis that magnesium deficiency plays a role in pre-eclampsia and the importance of serum magnesium levels as marker of severity of pre-eclampsia has been proposed and investigated in several studies with controversial results [163–166]. While Standley et al. [163] observed that serum magnesium levels decrease earlier in women with pre-eclampsia, others, however, could not demonstrate significant differences when comparing pre-eclamptic to uncomplicated pregnancies [164–166].

Treatment. Since the early 1900s, pre-eclampsia has been treated with magnesium. Up until the present day, magnesium sulphate has remained the most frequently used agent in the management of pre-eclampsia and eclampsia [167]. Magnesium is the drug of choice to prevent convulsions in eclampsia [168]. This is not surprising because the placebo-controlled Magnesium Sulphate for Prevention of Eclampsia trial (MAGPIE) showed that magnesium sulphate decreased the risk of eclampsia significantly (by half) in pre-eclamptic women. The study included 10 141 women with pre-eclampsia in 175 hospitals in 33 countries and its data clearly demonstrated that magnesium sulphate has an important role in preventing and controlling eclampsia. Its effect on eclampsia was consistent regardless of severity of pre-eclampsia, stage of gestation and anticonvulsant therapy (Figure 5) [169].

Magnesium sulphate is also more effective than other anticonvulsants in the treatment of eclampsia. Data from a study with 2138 hypertensive pregnant women demonstrated that magnesium sulphate was superior to phenytoin when given prophylactically to prevent seizures [167]. This large clinical trial also showed a considerable reduction in the development of eclampsia [167]. The Collaborative Eclampsia Trial investigated which anticonvulsant would be the best for women with eclampsia and provided Level I evidence for magnesium sulphate in this setting [170]. Magnesium sulphate therapy resulted in a 52% lower risk of recurrent convulsions compared with diazepam and a 67% lower risk of recurrent convulsions compared with phenytoin. The effect was consistent regardless of severity of pre-eclampsia, stage of gestation and whether or not other anticonvulsants had been taken [170]. Although the use of magnesium sulphate for pre-eclampsia is well substantiated, there is little evidence with pre-eclampsia, others, however, could not demonstrate significant differences when comparing pre-eclamptic to uncomplicated pregnancies [164–166].
supporting its routine use in gestational hypertension. Shear et al. [157] mentioned that in their clinic, magnesium sulphate is often used in women with severe pre-eclampsia and in those who are at risk for becoming eclamptic. In patients with proteinuria or with mild pre-eclampsia, magnesium sulphate should be given according to the specific clinical needs of the individual patient [58].

Possible underlying mechanisms. Magnesium appears to trigger the release of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation [171, 172], which is synthesized by the endothelium of vessels [171, 172]. In pre-eclampsia, acute magnesium sulphate administration improved endothelial function [171] and a rapid fall in systemic vascular resistance followed. Subsequently, blood pressure decreased transiently and cardiac index increased [173].

• Magnesium sulphate has been successfully used for decades in the management of pre-eclampsia and eclampsia to prevent eclamptic seizures.
• Magnesium sulphate reduces the risk of eclampsia by half compared with placebo.
• Magnesium is preferred over diazepam or phenytoin for the treatment of eclampsia.

Summary

Associations between low serum magnesium levels and low dietary magnesium intake and an increased risk for diseases such as the metabolic syndrome, T2DM and hypertension and atherosclerosis have been shown in various epidemiological studies. However, an indication for the administration of magnesium as a therapeutic agent could only be confirmed for pre-eclampsia and specific forms of arrhythmias (Fig. 6).

Conflict of interest statement. H.G. received speakers’ or consultancy honoraria from and participated in clinical trials with Abbott, Amgen, Genzyme, Fresenius and Shire. C.W. has received speakers’ honoraria from Abbott, Fresenius, Genzyme, Mitsubishi and Shire.

References

1. de Baaij JHF, Hoenderop JGJ, Bindels RJM. Regulation of magnesium balance: lessons learned from human genetic disease. Clin Kidney J 2012; 5 (Suppl 1): 115–124
2. Nielsen FH, Lukasi HC. Update on the relationship between magnesium and exercise. Magnes Res 2006; 19: 180–189
3. Matias CN, Santos DA, Monteiro CP et al. Magnesium and strength in elite judo athletes according to intracellular water changes. Magnes Res 2010; 23: 138–141
4. Golf SW, Bender S, Gruttner J. On the significance of magnesium in extreme physical stress. Cardiovasc Drugs Ther 1998; 12 (Suppl 2): 197–202
5. Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2010; 74: 691–696
6. Roffe C, Sills S, Crome P et al. Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Med Sci Monit 2002; 8: CR326–CR330
7. Frasso R, Zarate M, Augustoskovi F et al. Magnesium for the treatment of nocturnal leg cramps: a crossover randomized trial. J Fam Pract 1999; 48: 868–871
8. Young GL, Jewell D. Interventions for leg cramps in pregnancy. Cochrane Database Syst Rev 2002; 1: CD000121
9. Nygaard IH, Valbo A, Pethick SV et al. Does oral magnesium substitution relieve pregnancy-induced leg cramps? Eur J Obstet Gynecol Reprod Biol 2008; 141: 23–26
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359
11. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473–486
12. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20: 182–189
13. Guerrero-Romero F, Rodriguez-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002; 39: 209–213
14. He K, Song Y, Belin RJ et al. Magnesium intake and the metabolic syndrome: epidemiologic evidence to date. J Cardio Metab Syndr 2006; 1: 351–355
15. Song Y, Ridker PM, Manson JE et al. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005; 28: 1438–1444
16. He K, Liu K, Daviglus ML et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 2006; 113: 1675–1682
17. Simmons D, Joshi S, Shaw J. Hypomagnesaemia is associated with diabetes: Not pre-diabetes, obesity or the metabolic syndrome. Diabetes Res Clin Pract 2010; 87: 261–266
18. Pham PC, Pham PM, Pham SV et al. Hypomagnesaemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366–373
19. McNair P, Christensen MS, Christiansen C et al. Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. Eur J Clin Invest 1982; 12: 81–85
20. Pham PC, Pham PM, Pham PA et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 2005; 63: 429–436
21. Paolillo G, Sgambaro S, Pizza G et al. Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care 1989; 12: 265–269
22. Kao WH, Folsom AR, Nieto FJ et al. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999; 159: 2151–2159
23. Lopez-Ridaura R, Willett WC, Rimm EB et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004; 27: 134–140
24. Song Y, Manson JE, Buring JE et al. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 59–65
25. Larsson SC, Wolk A. Magnesium intake and risk of type 2 diabetes: a meta-analysis. J Intern Med 2007; 262: 208–214
26. Villegas R, Gao YT, Dai Q et al. Dietary calcium and magnesium intakes and the risk of type 2 diabetes: the Shanghai Women’s Health Study. Am J Clin Nutr 2009; 89: 1059–1067
27. Schulze MB, Schulz M, Heidemann C et al. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 2007; 167: 956–965
28. Kirii K, Iso H, Date C et al. Magnesium intake and risk of self-reported type 2 diabetes among Japanese. J Am Coll Nutr 2010; 29: 99–106
69. Euser AG, Cipolla MJ. Resistance artery vasodilation to mag- nesium sulfate during pregnancy and the postpartum state. Am J Physiol Heart Circ Physiol 2005; 288: H1521–H1525
70. Nishio A, Gembrewald A, Altura BT et al. Comparative vas- dilator effects of magnesium salts on rat mesenteric arterioles and venules. Arch Int Pharmacodyn Ther 1989; 298: 139–163
71. Villamor E, Perez-Vizcaino F, Ruiz T et al. In vitro effects of magnesium sulfate in isolated intrapulmonary and mesenteric arteries of piglets. Pediatr Res 1996; 39: 1107–1112
72. Perades AJ, Torregrosa G, Salom JB et al. In vivo and in vitro effects of magnesium sulfate in the cerebrovascular bed of the goat. Am J Obstet Gynecol 1991; 165: 1534–1538
73. Altura BM, Zhang A, Altura BT. Magnesium, hypertensive vas- cular diseases, atherogenesis, subcellular compartmentation of Ca²⁺ and Mg²⁺ and vascular contractility. Miner Electro- lyte Metab 1993; 19: 323–336
74. Blackfan KD, Hamilton B. Uremia in acute glomerular neph- ritis. Boston Med Surg J 1925; 193: 617
75. Kawasaki T, Itoh K, Kawasaki M. Reduction in blood pressure effect with calcium and magnesium supplementa- tion for the management of essential hyperten- sion. Hypertens Res 1998; 21: 235–243
76. Itoh K, Kawasaki T, Nakamura M. The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects. Br J Nutr 1997; 78: 737–750
77. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of “syndrome X”. Am J Hypertens 1993; 6: 1235–1345
78. Dominguez LJ, Babgarallo M, Sowers JR et al. Magnesium responsiveness to insulin and insulin-like growth factor I in erythrocytes from normotensive and hypertensive subjects. J Clin Endocrinol Metab 1998; 83: 4402–4407
79. Yamamoto ME, Applegate WB, Klag MJ et al. Lack of blood pressure effect with calcium and magnesium supplementa- tion in adults with high-normal blood pressure results. Adults from Phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 96–107
80. Dickinson HO, Nicolson DJ, Campbell F et al. Magnesium supplementation for the management of essential hyper- tension in adults. Cochrane Database Syst Rev 2006; 3: CD004640
81. Rosanoff A. Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects. Magnes Res 2010; 23: 27–40
82. Whelton PK, Klag MJ. Magnesium and blood pressure: review of the epidemiologic and clinical trial experience. Am J Cardiol 1989; 63: 266–306
83. Ascherio A, Rimm EB, Giovannucci EL et al. A prospective study of nutritional factors and hypertension among US men. Circulation 1992; 86: 1475–1484
84. van Leer EM, Seidl JC, Kromhout D. Dietary calcium, potas- sium, magnesium and blood pressure in the Netherlands. Int J Epidemiol 1995; 24: 1117–1123
85. Simons-Morton DG, Hunsberger SA, Van HL et al. Nutrient intake and blood pressure in the Dietary Intervention Study in Children. Hypertension 1997; 29: 930–936
86. Stuehlinger HG. The wider use of magnesium. Eur Heart J 2001; 22: 713–714
87. Dyckner T, Wester PO. Effect of magnesium on blood pres- sure. Br Med J (Clin Res Ed) 1983; 286: 1847–1849
88. Widman L, Wester PO, Stegmayr BK et al. The dose-dependent reduction in blood pressure through administration of magnesium. A double blind placebo controlled cross-over study. Am J Hypertens 1993; 6: 41–45
89. Kawano Y, Matsuo H, Takashita S et al. Effects of magne- sium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32: 260–265
90. Motoyama T, Sano H, Fukuzaki H. Oral magnesium supple- mentation in patients with essential hypertension. Hyperten- sion 1989; 13: 227–232
91. Cappuccio FP, Markandu ND, Beynon GW et al. Lack of effect of oral magnesium on high blood pressure: a double blind study. Br Med J (Clin Res Ed) 1985; 291: 235–238
92. Henderson DG, Schierup J, Schodt T. Effect of magnesium supplementation on blood pressure and electrolyte concentra- tions in hypertensive patients receiving long term diuretic treatment. Br Med J (Clin Res Ed) 1986; 293: 664–665
93. Nowson CA, Morgan TO. Magnesium supplementation in mild hypertensive patients on a moderately low sodium diet. Clin Exp Pharmacol Physiol 1989; 16: 299–302
94. Ferrara LA, Iannuzzi R, Castaldo A et al. Long-term magne- sium supplementation in essential hypertension. Cardiology 1992; 81: 25–33
95. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572
96. Davis WH, Leary WP, Reyes AJ et al. Monotherapy with magnesium increases abnormal low density lipo- protein cholesterol: a clinical assay. Curr Ther Res 1984; 36: 341–346
97. Elin RJ. Magnesium metabolism in health and disease. Dis Mon 1988; 34: 161–218
98. Altura BM, Altura BT. Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Cell Mol Biol Res 1995; 41: 347–359
99. Seelig M. Magnesium Deficiency in the Pathogenesis of Disease: Early Roots of Cardiovascular, Skeletal, and Renal Abnormalities. New York, NY: Plenum Medical Book Co; 1980
100. Pachikian BD, Neyrinck AM, Deldicque L et al. Changes in intestinal bifidobacteria levels are associated with the in- flammatory response in magnesium-deficient mice. J Nutr 2010; 140: 509–514
101. Lin CY, Tsai PS, Hung YC et al. L-type calcium channels are involved in mediating the anti-inflammatory effects of mag- nesium sulphate. Br J Anaesth 2010; 104: 44–51
102. King DE. Inflammation and elevation of C-reactive protein: does magnesium play a key role? Magnes Res 2005; 22: 57–59
103. Liao F, Folsom AR, Brancati FL. Is low magnesium con- centration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480–490
104. Ford ES. Serum magnesium and ischaemic heart disease: findings from a national sample of US adults. Int J Epidemiol 1999; 28: 645–651
105. Hashimoto T, Abe M, Suda T et al. Serum magnesium, ambulatory blood pressure, and carotid artery alteration: the Ohasama study. Am J Hypertens 2010; 23: 1292–1298
106. Ascherio A, Rimm EB, Herron MA et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998; 98: 1198–1204
107. Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis, and survival. Clin Kidney J 2012; 5 (Suppl 1): 52–61
108. Schechter M. Magnesium and cardiovascular system. Magnes Res 2010; 23: 60–72
109. Singh RB, Rastogi SS, Sharma VK et al. Can dietary magne- sium modulate lipoprotein metabolism? Magnes Trace Elem 1990; 9: 255–264
110. Song Y, Li TY, van Dam RM et al. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 2007; 85: 1068–1074
Magnesium in disease

114. Johnson CJ, Peterson DR, Smith EK. Myocardial tissue concentrations of magnesium and potassium in men dying suddenly from ischemic heart disease. Am J Clin Nutr 1979; 32: 967–970

115. Koppel H, Gasser R, Spichiger U. [Free intracellular magnesium: role-state of the art]. Wien Med Wochenschr 2000; 150: 321–324

116. Kircelli F, Peter ME, Sevinc OE et al. Magnesium in acute myocardial infarction: overview of available evidence. Am Heart J 1996; 132: 487–495

117. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am J Heart J 1984; 108: 188–193

118. Shechter M. Does magnesium have a role in the treatment of patients with coronary artery disease? Am J Cardiovasc Drugs 2003; 3: 231–239

119. Woods KL, Fletcher S, Roffe C et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553–1558

120. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816–819

121. Shechter M, Hod H, Chouraqui P et al. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolysis. Am J Cardiol 1995; 75: 321–323

122. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival 4). Lancet 1995; 345: 669–685

123. Teo KK, Yusuf S, Collins R et al. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991; 303: 1499–1503

124. Seeilig MS. Magnesium in acute myocardial infarction (International Study of Infarct Survival 4). Am J Cardiol 1991; 68: 1221–1222

125. Antman EM. Magnesium in acute MI. Timing is critical. Circulation 1995; 92: 2367–2372

126. Santoro GM, Antonucci D, Bolognese L et al. A randomized study of intravenous magnesium in acute myocardial infarction treated with direct coronary angioplasty. Am Heart J 2000; 140: 891–897

127. The Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360: 1189–1196

128. Millane TA, Ward DE, Camm AJ. Is hypomagnesemia arrhythmogenic? Clin Cardiol 1992; 15: 103–108

129. DeCarli C, Sprovie G, LaRosa JC. Serum magnesium levels in symptomatic atrial fibrillation and their relation to rhythm control by intravenous digoxin. Am J Cardiol 1986; 57: 956–959

130. Agus MS, Agus ZS. Cardiovascular actions of magnesium. Crit Care Clin 2001; 17: 175–186

131. Zehender M, Meintert Z, Faber T et al. Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA) Investigators. J Am Coll Cardiol 1997; 29: 1028–1034

132. Abraham AS, Rottmann D, Kramer M et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987; 147: 753–755

133. Parikka H, Toivonen L, Naukkarinen V et al. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction. Eur Heart J 1999; 20: 111–120

134. Rasmussen HS, Suenson M, McNair P et al. Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction. A double-blind placebo-controlled study. Clin Cardiol 1987; 10: 351–356

135. Horner SM. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction. Circulation 1992; 86: 774–779

136. Zipes DP, Camm AJ, Borggreve M et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e385–e484

137. Nolan JP, De Latorre FJ, Steen PA et al. Advanced life support drugs: do they really work? Curr Opin Crit Care 2002; 8: 212–218

138. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999; 83: 302–320

139. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002; 112: 58–66

140. Kaye P, O’Sullivan I. The role of magnesium in the emergency department. Emerg Med J 2002; 15: 288–291

141. Roden DM. A practical approach to torsade de pointes. Clin Cardiol 1997; 20: 285–290

142. Tzivoni D, Keren A. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol 1990; 65: 1397–1399

143. Tzivoni D, Keren A, Cohen AM et al. Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53: 528–530

144. Drew BJ, Ackerman MJ, Funk M et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047–1060

145. Young IS, Goh EM, McKillop UH et al. Magnesium status and digoxin toxicity. Br J Clin Pharmacol 1991; 32: 717–721

146. Kinlay S, Buckley NA. Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity. J Toxicol Clin Toxicol 1995; 33: 55–59

147. Cecco SA, Hristova EN, Rehak NN et al. Clinically important intermethod differences for physiologically abnormal ionized magnesium results. Am J Clin Pathol 1997; 108: 564–569

148. Keller PK, Aronson RS. The role of magnesium in cardiac arrhythmias. Prog Cardiovasc Dis 1980; 23: 433–448

149. Zivlakler L. Ueber die Magnesiumwirkung auf das Herz. Klinische Wochenschrift 1935; 14: 1429–1433

150. Kaplan M, Kut MS, Icer UA et al. Intravenous magnesium sulfate prophylaxis for atrial fibrillation after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 344–352

151. Iseri LT, Fairsheter RD, Hardermann JL et al. Magnesium and potassium therapy in multifocal atrial tachycardia. Am Heart J 1985; 110: 789–794

152. Frick M, Dørbo B, Ostergren J et al. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion...
in patients with persistent atrial fibrillation. Eur Heart J 2000; 21: 1177–1185

153. Viskin S, Belhassen B, Sheps D et al. Clinical and electrophysiologic effects of magnesium sulfate on paroxysmal supraventricular tachycardia and comparison with adenosine triphosphate. Am J Cardiol 1992; 70: 879–885

154. Verma YS, Chauhan S, Gharde P et al. Role of magnesium in the prevention of postoperative arrhythmias in neonates and infants undergoing arterial switch operation. Interact Cardiovasc Thorac Surg 2010; 11: 573–576

155. Buhimschi IA, Saade GR, Chwalisz K et al. The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update 1998; 4: 25–42

156. Greene MF. Magnesium sulfate for preeclampsia. N Engl J Med 2003; 348: 275–276

157. Shear R, Leduc L, Rey E et al. Hypertension in pregnancy: new recommendations for management. Curr Hypertens Rep 1999; 1: 529–539

158. Hibbard JU. Hypertensive disease and pregnancy. J Hypertens Suppl 2002; 20: S29–S33

159. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341: 1447–1451

160. Kisters K, Barenbrock M, Louwen F et al. Membrane, intracellular, and plasma magnesium and calcium concentrations in preeclampsia. Am J Hypertens 2000; 13: 765–769

161. Brown MA. The physiology of preeclampsia. Clin Exp Pharmacol Physiol 1995; 22: 781–791

162. Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int 2009; 76: 831–837

163. Standley CA, Whitty JE, Mason BA et al. Serum ionized magnesium levels in normal and preeclamptic gestation. Obstet Gynecol 1997; 89: 24–27

164. Handwerker SM, Altura BT, Altura BM. Ionized serum magnesium and potassium levels in pregnant women with preeclampsia and eclampsia. J Reprod Med 1995; 40: 201–208

165. Frenkel Y, Weiss M, Shefi M et al. Mononuclear cell magnesium content remains unchanged in various hypertensive disorders of pregnancy. Gynecol Obstet Invest 1994; 38: 220–222

166. Seydoux J, Girardin E, Paunier L et al. Serum and intracellular magnesium during normal pregnancy and in patients with pre-eclampsia. Br J Obstet Gynaecol 1992; 99: 207–211

167. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995; 333: 201–205

168. James MF. Magnesium in obstetrics. Best Pract Res Clin Obstet Gynaecol 2010; 24: 327–337

169. Altman D, Car roi G, Duley L et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877–1890

170. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345: 1455–1463

171. Roberts JM, Taylor RN, Musci TJ et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200–1204

172. Nadler JL, Goodson S, Rude RK. Evidence that prostacyclin mediates the vascular action of magnesium in humans. Hypertension 1987; 9: 379–383

173. Scardo JA, Hogg BB, Newman RB. Favorable hemodynamic effects of magnesium sulfate in preeclampsia. Am J Obstet Gynecol 1995; 173: 1249–1253